Inflammatory and angiogenic signaling pathways

Inflammatory and angiogenic signaling pathways represent a complex network of interconnected biochemical cascades that regulate the body's response to injury and the formation of new blood vessels. Inflammation involves the activation of signaling cascades, such as NF-κB and JAK/STAT, by cytokines like TNF-α and IL-6, which recruit immune cells to sites of damage (Source: StatPearls, Inflammation). Angiogenesis, the growth of new blood vessels from existing ones, is primarily driven by factors such as Vascular Endothelial Growth Factor (VEGF) (Source: NIH, Angiogenesis). These processes are mutually reinforcing; inflammatory cells often secrete pro-angiogenic factors, while the resulting leaky vasculature facilitates further inflammatory cell infiltration (Source: PubMed, PMID: 23811249). In pathological states like cancer and chronic inflammatory diseases, these pathways are dysregulated, driving tumor growth, metastasis, and tissue destruction. Therapeutic strategies often involve targeting specific nodes within these pathways, such as VEGF or TNF-α, to restore physiological balance (Source: PubChem). However, because these pathways are fundamental to normal homeostasis, systemic inhibition can lead to significant side effects, including impaired healing and cardiovascular complications.

Other names

Inflammation-angiogenesis axisPro-inflammatory and pro-angiogenic signalingAngio-inflammatory signaling

Drugs targeting these pathways function by neutralizing circulating ligands (e.g., anti-VEGF or anti-TNF antibodies), blocking cell-surface receptors (e.g., tyrosine kinase inhibitors), or inhibiting intracellular signaling enzymes like Janus kinases (JAKs) and cyclooxygenases (COX) to reduce the production of inflammatory and angiogenic mediators (Source: PubMed, PMID: 30214694).